#United States #cancer therapy #San Jose #biotechnology #Anixa

Anixa Biosciences' Presentation on CAR-T Therapy for Ovarian Cancer

Anixa Biosciences, headquartered in San Jose, California, is making waves in cancer treatment with its cutting-edge CAR-T therapy targeting ovarian cancer. On December 14, 2026, Dr. Robert Wenham, the head of the Gynecologic Oncology Program at Moffitt Cancer Center, will present the company's latest findings at the prestigious ESMO (European Society of Medical Oncology) Immuno-Oncology Congress in London. This event is renowned for bringing together top minds in cancer research and treatment, making it an ideal platform for Anixa to showcase its promising advancements.

The spotlight will be on Anixa's Phase 1 clinical trial, which explores the efficacy of a novel CAR-T therapy designed to combat recurrent ovarian cancer. This therapy focuses on genetically engineering a patient's own T cells to target the follicle-stimulating hormone receptor (FSHR), a marker found on malignant ovarian cells but with minimal presence in healthy tissues. This innovative strategy holds great potential, as it could minimize collateral damage to non-cancerous cells during treatment.

The clinical trial, identified by ClinicalTrials.gov under NCT05316129, has already progressed significantly. Anixa recently completed treatment for its fifth group of participants, who received what is referred to as a high-dose regimen of CAR-positive cells. The dosage they received—1x10⁷ cells per kilogram of body weight—represents a remarkable increase from earlier treatments. The team is pleased to report no dose-limiting toxicities, which is a promising indicator for the safety of this new therapy.

Additionally, interim results are encouraging, with some patients exhibiting stable disease after 90 days of treatment, and others surviving for over a year. One remarkable case even highlights a patient who has surpassed two years post-treatment, showcasing the potential impact of this novel approach.

Dr. Amit Kumar, CEO of Anixa Biosciences, expressed enthusiasm about the upcoming presentation. He noted the importance of sharing the trial's advancements with the global oncology community and emphasized the hope that greater understanding could lead to improved treatment modalities for patients facing recurrent ovarian cancer.

The ESMO Congress serves as a crucial meeting for healthcare professionals to exchange insights on the latest innovations in cancer immunotherapy. Researchers and clinicians from around the globe will gather to discuss current findings and future directions in the fight against cancer, focusing on the role of cellular therapies and immunotherapeutics.

Anixa's commitment to advancing its CAR-T therapy for ovarian cancer signifies a critical step forward not only for the company but also for the broader oncology community that strives to innovate treatments for challenging cancers.

Anixa Biosciences continues to build its reputation as a leader in the biotechnology landscape, primarily through partnerships with esteemed institutions like Moffitt Cancer Center. Their collaborative efforts have led to breakthroughs not just in ovarian cancer therapy but also in immunization strategies against various other malignancies, such as breast cancer.

For further updates on the trial and additional company advancements, interested parties can visit Anixa's official website or follow their social media channels.

In conclusion, the upcoming ESMO 2026 presentation is a turning point for Anixa Biosciences, hinting at a future where innovative cancer treatments may become the norm, bringing hope to many patients around the world.